Browsing Tag
congenital hyperinsulinism
2 posts
Rhythm Pharmaceuticals (RYTM) TRANSCEND trial in NEJM shows 19.8% placebo-adjusted BMI reduction
Rhythm Pharma (RYTM) TRANSCEND Phase 3 published in NEJM validates IMCIVREE for acquired hypothalamic obesity. 10,000-patient US market launch trajectory ahead.
Rezolute shares plunge after Phase 3 sunRIZE study fails to show significant benefit in congenital hyperinsulinism
Rezolute shares collapsed after its Phase 3 sunRIZE trial failed in congenital hyperinsulinism. Find out what went wrong and what it means for investors now.